## Date of Completion: **PEDE Quality Appraisal Questionnaire** dd mm yyyy **Initials Data Entry Complete:** \_\_\_/\_\_/ dd mm yyyy Initials Citation Information ID #: Title: **Economic Evaluation** 'Consequences' refers to impact on health, 1. Is the research question posed in terms of costs and health status, well-being, disease incidence, consequences? etc. It does not include monetary benefits, such as savings. 1. Yes (explicitly stated) The research question should appear in the 2. Yes (inferred from text, tables, or figures) body of the text (not merely title or abstract). ☐ 3. No CMA, CEA, CBA, CUA or Cost-consequence 2. Is a specific type of economic analysis technique analysis (CCA). performed? An analytic technique should be specified, beyond the use of 'cost-effective' or 'cost-1. Yes (explicitly stated) 2. Yes (inferred from text, tables, or figures) benefit' as a generality or adjective. □ 3. No 3. What type of analytic technique is performed, according to the authors?

☐ 1. CMA

☐ 2. CEA

4. CUA

Comparators

☐ 3. No

☐ 3. No

5. Cost-consequence analysis

7. Other (Specify:

4. Is there a rationale for choosing the intervention(s)

2. Yes (inferred from text, tables, or figures)

5. Is there a rationale for choosing the alternative

2. Yes (inferred from text, tables, or figures)

program(s) or intervention(s) used for comparison?

☐ 6. Unknown/can't tell

being investigated?

1. Yes (explicitly stated)

1. Yes (explicitly stated)

☐ 3. CBA

sometimes be inferred.

(Check all that apply)

Indicate what the authors state is performed,

even though they may be incorrect, such as

(Errors in identifying the technique or valuing

labeling as a CBA what is actually a CEA.

The rationale for comparators that are 'do

nothing' or 'usual care' or pre-intervention practice may not be explicitly stated but may

the outcomes are addressed in Q38).

What are the setting, mode of delivery and	6. Does the report describe the alternatives in adequate detail?
timing of the investigational intervention(s) and comparator(s)? What is the dosing or administration regimen or intensity of exposure?	<ul> <li>☐ 1. Yes (explicitly stated)</li> <li>☐ 2. Yes (inferred from text, tables, or figures)</li> <li>☐ 3. No</li> </ul>
Are details describing disease and treatment- related events following the intervention(s) provided? For comparisons of screening interventions for detection of cases, the treatment pathway may not be described (not applicable). If screening is followed by treatment, or for prevention studies, an event pathway should be described.	7. Is a description of the event pathway provided?  1. Yes (explicitly stated) 2. Yes (inferred from text, tables, or figures) 3. No 4. Not applicable
Were costs and consequences modeled in a decision tree with chance node probabilities derived from a variety of sources or established directly from a specific patient population? Includes Markov models. A decision analysis may have been performed even if the tree is not depicted.	8. Is a formal decision analysis performed?  1. Yes (explicitly stated) 2. Yes (inferred from text, tables, or figures) 3. No 4. Unknown/Not stated
	Target Population
For whom will the intervention be of value? What is the population for which an allocation decision is required?	Is the target population for the intervention identified?
·	<ul> <li>☐ 1. Yes (explicitly stated)</li> <li>☐ 2. Yes (inferred from text, tables, or figures)</li> <li>☐ 3. No</li> <li>☐ 4. Not applicable</li> </ul>
Is the study sample similar to the target population with respect to age, sex, severity of	10. Are the subjects representative of the population to which the intervention is targeted?
Is the study sample similar to the target population with respect to age, sex, severity of disease, co-morbidities, health care system jurisdiction and other characteristics relevant to the intervention and research question? If the subjects are purely hypothetical, then indicate 'Not applicable'.	10. Are the subjects representative of the population to
population with respect to age, sex, severity of disease, co-morbidities, health care system jurisdiction and other characteristics relevant to the intervention and research question? If the subjects are purely hypothetical, then indicate	10. Are the subjects representative of the population to which the intervention is targeted?  1. Yes (explicitly stated) 2. Yes (inferred from text, tables, or figures) 3. No 4. Unknown/Not stated/Can't tell

The time frame should be long enough to capture all significant benefits, harms, and costs and relevant periods of child development. If no time horizon is stated, the response is 'no'.	12. Do the authors justify the time horizon selected?  1. Yes (explicitly stated) 2. Yes (inferred from text, tables, or figures) 3. No
	Perspective
	13. Is a perspective for the analysis given?
	<ul> <li>☐ 1. Yes (explicitly stated)</li> <li>☐ 2. Yes (inferred from text, tables, or figures)</li> <li>☐ 3. No</li> </ul>
	14. Is a societal perspective taken, either alone or in addition to other perspectives?
	<ul> <li>☐ 1. Yes (explicitly stated)</li> <li>☐ 2. Yes (inferred from text, tables, or figures)</li> <li>☐ 3. No</li> <li>☐ 4. Unknown/Not stated</li> </ul>
If only one perspective was studied, then check 'Not applicable'.	15. When there was more than one perspective, are the results of each perspective presented separately?
	<ul> <li>☐ 1. Yes (explicitly stated)</li> <li>☐ 2. Yes (inferred from text, tables, or figures)</li> <li>☐ 3. No</li> <li>☐ 4. Not applicable</li> </ul>
Door the renge of costs conjuntally reflect the	Costs and Resource Use
Does the range of costs accurately reflect the perspective? When necessary, were fixed,	16. Are all relevant costs for each alternative included?
capital costs and overhead costs included? Were costs incurred or averted related to subsequent follow-up and treatment of disease or complications considered?	☐ 1. Yes (explicitly stated) ☐ 2. Yes (inferred from text, tables, or figures) ☐ 3. No
In a societal perspective, these may be included as cost items (in the numerator) or as part of utility assessment (in the denominator).	17. Are opportunity costs of lost time (productivity costs) for parents and informal caregivers measured when required?
A patient or family perspective may also require these costs, if the lost time results in an income loss to the individual. For other perspectives, indicate 'Not applicable'. These costs may appear in the base case or in a sensitivity analysis.	<ul> <li>☐ 1. Yes (explicitly stated)</li> <li>☐ 2. Yes (inferred from text, tables, or figures)</li> <li>☐ 3. No</li> <li>☐ 4. Unknown/Not stated</li> <li>☐ 5. Not applicable</li> </ul>

This would be expected for interventions such as screening or vaccination programs, that are directed at school age children. Interventions related to learning or behaviour would also involve school and/or community resources.	<ul> <li>18. Do cost item identification and valuation extend beyond the health care system to include school and community resources when necessary?</li> <li>1. Yes (explicitly stated)</li> <li>2. Yes (inferred from text, tables, or figures)</li> <li>3. No</li> <li>4. Unknown/Not stated</li> </ul>
Either within the stated time horizon of the study or a time horizon that is clearly appropriate for the research question.	S. Not applicable     19. Are future salary and productivity changes of the child taken into consideration when appropriate?
This is relevant for papers that state that the prevention or treatment of the condition may impact on lifetime productivity as part of the rationale for doing the study.	<ul> <li>1. Yes (explicitly stated)</li> <li>2. Yes (inferred from text, tables, or figures)</li> <li>3. No</li> <li>4. Unknown/Not stated</li> <li>5. Not applicable</li> </ul>
Examples: questionnaires, interviews, chart abstraction, administrative databases, literature.	20. Were all of the sources for estimating the volume of resource use described?
If some sources were missing or not mentioned, indicate 'No'.	<ul> <li>1. Yes (explicitly stated)</li> <li>2. Yes (inferred from text, tables, or figures)</li> <li>3. No</li> </ul>
Possible sources include fee schedules, formularies, patient self-report, standard cost lists, wholesaler catalogues, case-costing	21. Were all the sources for estimating all of the unit costs described?
databases, references to other costing papers. If some sources were missing or not mentioned, indicate 'No'.	<ul> <li>1. Yes (explicitly stated)</li> <li>2. Yes (inferred from text, tables, or figures)</li> <li>3. No</li> </ul>
	Outcomes
For example, cases detected, for a screening intervention.	22. Is a primary health outcome given?
	<ul> <li>1. Yes (explicitly stated)</li> <li>2. Yes (inferred from text, tables, or figures)</li> <li>3. No</li> </ul>
	23. Do the authors justify the health outcome(s) selected?
	<ul> <li>☐ 1. Yes (explicitly stated)</li> <li>☐ 2. Yes (inferred from text, tables, or figures)</li> <li>☐ 3. No</li> </ul>
Effectiveness = routine use in a diverse population; Efficacy = experimentally controlled	24. Is effectiveness, rather than efficacy assessed?
use in a uniform population For screening interventions, effectiveness may be expressed as sensitivity and specificity. "Efficacy" is sometimes the term used when "effectiveness" is really what is measured.	<ul> <li>1. Yes (explicitly stated)</li> <li>2. Yes (inferred from text, tables, or figures)</li> <li>3. No</li> <li>4. Unknown/Not stated/Can't tell</li> </ul>

(Check all that apply)	25. What approach was used to assess the effectiveness/efficacy?
Prospective may include clinical trials or observational studies using surveys or questionnaires. Retrospective may include chart reviews, or databases (insurance claims, prior surveys, completed studies). Prospective or retrospective data collection may involve examining data from the study institution.	<ul> <li>□ 1. Prospective data collection</li> <li>□ 2. Retrospective data collection</li> <li>□ 3. Literature sources</li> <li>□ 4. Expert opinion</li> <li>□ 5. Other (Specify:</li></ul>
Citation of a reference is inadequate (indicate 'No') as this does not permit evaluation of the quality of the evidence.	26. Are the details of the design of the effectiveness/efficacy study(s) provided?   1. Yes (explicitly stated)
	<ul> <li>2. Yes (inferred from text, tables, or figures)</li> <li>3. No</li> <li>4. Not applicable</li> </ul>
This is also relevant for a CMA.	27. Are the results of the efficacy/effectiveness of alternatives reported?
	<ul> <li>☐ 1. Yes (explicitly stated)</li> <li>☐ 2. Yes (inferred from text, tables, or figures)</li> <li>☐ 3. No</li> <li>☐ 4. Not applicable</li> </ul>
Measurement of absences may not be	28. Are school/day care absences taken into consideration?
applicable to studies of very young children or studies where the outcome is 'cases detected/prevented'. Measurement of absences may be a cost item to represent parental work absences or a health status/function measure.	<ul> <li>☐ 1. Yes (explicitly stated)</li> <li>☐ 2. Yes (inferred from text, tables, or figures)</li> <li>☐ 3. No</li> <li>☐ 4. Not applicable</li> </ul>
Almost all outcomes are intermediate and include: cases detected, lab or physical function measures, symptom reduction,	29. If intermediate outcome variables are used, are they linked by evidence or reference to the end benefit?
complication rate. End benefit would be survival or life years gained. There must be evidence to link or extrapolate the intermediate measure to the final value for survival or life years gained. For CMA, check 'not applicable'.	<ul> <li>☐ 1. Yes (explicitly stated)</li> <li>☐ 2. Yes (inferred from text, tables, or figures)</li> <li>☐ 3. No</li> <li>☐ 4. Not applicable</li> </ul>
(Check all that apply) If not measured, check 'Not applicable'.	Quality of Life
Standard generic instruments include the SF- 36 and Child Health Questionnaire. If quality of	30. If quality of life was measured, what type of instrument was used?
life was part of a utility assessment, this is considered generic, preference-based. Direct preference includes standard gamble, time trade-off and visual analog. Indirect preference includes HUI, QWB. EQ-5D, EuroQol.	<ul> <li>1. Disease-specific</li> <li>2. Generic, standard instrument</li> <li>3. Generic, direct preference</li> <li>4. Generic, indirect preference</li> <li>5. Other (Specify:)</li> <li>6. Not applicable</li> </ul>

	31. Whose quality of life was assessed?
(Check all that apply)  For studies that include both children and adults, indicate the response relevant to the pediatric evaluation.	<ul> <li>☐ 1. Child</li> <li>☐ 2. Parent</li> <li>☐ 3. Caregiver (if OTHER than parent)</li> <li>☐ 4. Other (Specify:</li></ul>
(Check all that apply)	32. Who performed the quality of life assessment?  1. Self assessment (child, parent or caregiver) 2. Parent on behalf of child 3. Caregiver on behalf or child 4. Health provider on behalf of child 5. Other (Specify:) 6. Not applicable
For example, costs should be measured in a currency unit and outcomes should be expressed as a natural unit for CEA, QALY (or equivalent) for CUA and currency unit for CBA.  If only costs or only outcomes are measured in appropriate units, then indicate 'No'.	Analysis  33. Were costs AND outcomes measured in units appropriate for the indicated analytic technique?  ☐ 1. Yes (explicitly stated) ☐ 2. Yes (inferred from text, tables, or figures) ☐ 3. No ☐ 4. Unknown/Not stated
(Check all that apply)  If data collection was retrospective (e.g. charts, database, literature), then check 'Not applicable'.  The age limit for direct elicitation of responses may vary from study to study. For infants, indicate 'Not applicable'. For studies of interventions administered to pregnant or breastfeeding women, indicate 'Not applicable'.	34. For prospective studies that used interviews, questionnaires or surveys, how were data obtained in studies involving young children?  1. Directly 2. Parent proxy 3. Other proxy (specify:) 4. Joint measure (specify:) 5. Not applicable
(Check all that apply)	35. How were direct costs valued?  1. Opportunity cost 2. Fixed, overhead, capital or administrative costs 3. Charges or fees 4. Deflated charges (using cost to charge ratios) 5. Market or wholesale prices, replacement costs 6. Average cost (per patient day, etc.) 7. Assumption, opinion, expert panel 8. Unknown/Not stated 9. Other method (specify:)

(Check all that apply)	36. How were productivity costs valued?
Two types of Human Capital Approach:  1. Market value = cost to hire a person, e.g. homemaker, to perform labour  2. Opportunity cost = earned income if caregiver was in workforce  Valuation may pertain to parent or caregiver or	<ul> <li>☐ 1. Market value approach</li> <li>☐ 2. Opportunity cost approach</li> <li>☐ 3. Average statistical wage from population database</li> <li>☐ 4. Friction cost method</li> <li>☐ 5. Other method (specify:)</li> <li>☐ 6. Not applicable</li> </ul>
child's future earnings.	27 Ware costs valued appropriately 2
When necessary, were adjustments for inflation or currency conversion made? Were costs allocated properly? Where market values were absent (e.g. volunteers), or market values did not reflect actual values, were adjustments made to approximate market values?	37. Were costs valued appropriately?  ☐ 1. Yes (explicitly stated) ☐ 2 Yes (inferred from text, tables, or figures) ☐ 3. No ☐ 4. Unknown/Not stated/Can't tell
For example, in CBA, was the outcome monetarized using willingness-to-pay or other method? Health	38. Was the valuation of outcomes appropriate for the type of analysis?
care savings resulting from disease prevention is insufficient as a monetarized outcome in CBA. For CUA, was utility assessed using a valid instrument or method? If assumptions or expert opinion was used to assign values for utilities or other outcome measures, indicate 'No'.	<ul> <li>☐ 1. Yes (explicitly stated)</li> <li>☐ 2. Yes (inferred from text, tables, or figures)</li> <li>☐ 3. No</li> <li>☐ 4. Unknown/Not stated/Can't tell</li> </ul>
Check all that apply	39. What was the unit of analysis used for expressing
Check all that apply.  If the unit costs or an intermediate step express the result per patient but the final result is per population, indicate only 'per population'. If the result is expressed per study sample, then extrapolated to the population, check both. "Per family" refers to costs incurred by multiple members. "Per joint parent-child" refers to a single measure developed to link the parent and child.	39. What was the unit of analysis used for expressing the <b>final</b> results?  1. Per child or patient or case 2. Per parent 3 Per family 4. Per joint parent-child 5. Per patient sample or study sample 6. Per population (e.g. per 10,000 or whole population)
If the unit costs or an intermediate step express the result per patient but the final result is per population, indicate only 'per population'. If the result is expressed per study sample, then extrapolated to the population, check both. "Per family" refers to costs incurred by multiple members. "Per joint parent-child" refers to a single measure developed to link the parent	the <b>final</b> results?  1. Per child or patient or case 2. Per parent 3 Per family 4. Per joint parent-child 5. Per patient sample or study sample 6. Per population (e.g. per 10,000 or whole
If the unit costs or an intermediate step express the result per patient but the final result is per population, indicate only 'per population'. If the result is expressed per study sample, then extrapolated to the population, check both. "Per family" refers to costs incurred by multiple members. "Per joint parent-child" refers to a single measure developed to link the parent and child.  In the case of decision analysis, if probabilities of events are stated explicitly with a description of the consumption of resources associated	the <b>final</b> results?  1. Per child or patient or case 2. Per parent 3 Per family 4. Per joint parent-child 5. Per patient sample or study sample 6. Per population (e.g. per 10,000 or whole population)  40. Were quantities of resources used reported separately from their unit costs?  1. Yes (explicitly stated) 2. Yes (inferred from text, tables, or figures) 3. No

	42. Were details of statistical tests and confidence intervals given for stochastic data?
	<ul> <li>☐ 1. Yes (explicitly stated)</li> <li>☐ 2. Yes (inferred from text, tables, or figures)</li> <li>☐ 3. No</li> <li>☐ 4. Not applicable</li> </ul>
	Discounting
Discounting is not required if the time horizon is less than or equal to 1 year (indicate 'Not applicable').	43. When required, were costs and consequences that occur over more than one year discounted to their present values?
If only costs but not benefits were discounted, check 'No'.	<ul> <li>☐ 1. Yes (explicitly stated)</li> <li>☐ 2. Yes (inferred from text, tables, or figures)</li> <li>☐ 3. No</li> <li>☐ 4. Unknown/Not stated</li> <li>☐ 5. Not applicable</li> </ul>
If the time horizon was less than or equal to 1 year, check 'Not applicable'. If time horizon was greater than 1 year and costs and benefits were discounted, check 'Not applicable'. If an explanation was not provided for benefits when costs alone were discounted, check 'No'.	<ul> <li>44. If costs or benefits were not discounted when the time horizon exceeded 1 year, was an explanation provided?</li> <li>1. Yes (explicitly stated)</li> <li>2. Yes (inferred from text, tables, or figures)</li> <li>3. No</li> <li>4. Not applicable</li> </ul>
	Incremental Analysis
	45. Are incremental estimates of costs and outcomes presented?
	<ul> <li>☐ 1. Yes (explicitly stated)</li> <li>☐ 2. Yes (inferred from text, tables, or figures)</li> <li>☐ 3. No</li> <li>☐ 4. Not applicable</li> </ul>
Were the additional cost generated by one alternative over another compared to the additional effects generated?	46. Are the incremental estimates summarized as incremental ratios?
An incremental ratio is 'not applicable' when one alternative is dominant over the other or when a CMA is conducted. A CBA can be expressed either as a ratio or a linear equation.	<ul> <li>☐ 1. Yes (explicitly stated)</li> <li>☐ 2. Yes (inferred from text, tables, or figures)</li> <li>☐ 3. No</li> <li>☐ 4. Not applicable</li> </ul>
If incremental estimates for costs and outcomes (separate or in a ratio) were not reported, then check 'No'.	47. Were confidence intervals/limits calculated for incremental ratios or incremental estimates of costs and outcomes?

	1. Yes (explicitly stated)
	2. Yes (inferred from text, tables, or figures)
	☐ 3. No
<u>.</u>	Sensitivity Analysis
(e.g. discount rates, missing or imprecise resource use, missing prices)	48. Were all important assumptions given?
	☐ 1. Yes (explicitly stated)
	2. Yes (inferred from text, tables, or figures)
	3. No
	49. Was a sensitivity analysis performed?
	1. Yes (explicitly stated)
	2. Yes (inferred from text, tables, or figures)
	☐ 3. No
	FO De the south and in official and the south and a
	50. Do the authors justify the alternative values or ranges for sensitivity analysis?
If a sensitivity analysis was not performed, then	ranges for sensitivity analysis!
check 'No'.	1. Yes (explicitly stated)
oneon ito:	2. Yes (inferred from text, tables, or figures)
	3. No
	51. What methods were used to assess uncertainty?
Check all that apply.	
	1. One-way sensitivity analysis
	2. Two-way sensitivity analysis
	3. Multi-way sensitivity analysis
	<ul><li>4. Bootstrapping or Monte Carlo simulations</li><li>5. Other (Specify:</li></ul>
	6. None performed
	C. None penemica
For a statement of funding support in the	Conflict of Interest
Acknowledgements, Title page or footnote,	52. Does the paper present the relationship with the
indicate 'Yes (explicitly stated)'.	sponsor of the study?
	1. Yes (explicitly stated)
	2. Yes (inferred from text, tables, or figures)
	☐ 3. No
	53. Does the paper indicate that the authors had
If the sponsor is a government granting agency	independent control over the methods and right to
or the research was performed independently	publish?
(self-supported) then response is 'not	
applicable'. If nothing is indicated, check 'No'.	1. Yes (explicitly stated)
	2. Yes (inferred from text, tables, or figures)
	☐ 3. No
	4. Not applicable
	4. Not applicable Conclusions
	i · · · · · · · · · · · · · · · · · · ·

	☐ 1. Yes (explicitly stated) ☐ 2. Yes (inferred from text, tables, or figures) ☐ 3. No
	55. Are the most important limitations of the study discussed?
	<ul> <li>☐ 1. Yes (explicitly stated)</li> <li>☐ 2. Yes (inferred from text, tables, or figures)</li> <li>☐ 3. No</li> </ul>
This relates to how the information derived from the study can be used for allocation	56. Do the authors generalize the conclusions to other settings or patient/client groups?
decisions.	<ul> <li>☐ 1. Yes (explicitly stated)</li> <li>☐ 2. Yes (inferred from text, tables, or figures)</li> <li>☐ 3. No</li> </ul>
	57. Global impression of the quality of the paper.
	<ul> <li>☐ 1. Excellent</li> <li>☐ 2. Very Good</li> <li>☐ 3. Good</li> <li>☐ 4. Fair</li> <li>☐ 5. Poor</li> <li>☐ 6. Worthless</li> </ul>